UK: English High Court Dismisses Interim Injunction In Abuse Of Dominance Case Concerning Refusal To Supply In HIV Prescription Medicines Market

On 11 February 2013, the English High Court dismissed an application for an interim injunction in an abuse of dominance case concerning an alleged refusal to supply a patented HIV prescription medicine.

Chemistree Homecare Ltd (the "claimant") had applied for an interim injunction against Abbvie Ltd (the "defendant") concerning supplies of a patented medical product marketed under the brand name Kaletra®, a protease inhibitor used in combination therapies of antiretroviral ("ARV") medicines for HIV patients. The claimant is a pharmacy business, primarily involved in the supply of homecare services to NHS hospitals but also in dispensing medicines and delivering them to patients' homes and administering them to patients. It is also active as a medical wholesaler. The defendant supplies and distributes Kaletra® in the UK.

In 2005, the claimant was awarded a contract to provide pan-London HIV pharmacy home delivery services in cooperation with NHS hospitals. As a result, the claimant approached the defendant and opened an account for the supply of Kaletra®, expressly for the purpose of fulfilling its obligations under the contract. Use of Kaletra® steadily increased over time and, by 2012, faced with a shortage of supplies in the UK, the defendant requested information from the claimant regarding its NHS supply contracts and requirements for Kaletra®. After several exchanges, the claimant eventually revealed in January 2013 that less than 15% of its requirements for Kaletra® were to cover UK prescriptions related to its homecare services, and that over 38% actually represented demand for wholesale supply to cover prescriptions in Lithuania.

On learning about this, the defendant refused to supply the claimant with Kaletra® other than for the provision of homecare services. It still supplied quantities above those needed for the provision of homecare services, but considerably lower than what the claimant had ordered in December 2012. In response, the claimant, insisting that such an alleged refusal to supply was unlawful, began proceedings before the High Court, on the grounds that the defendant had abused its dominant position, in breach of Article 102 TFEU and the Chapter II prohibition of the UK Competition Act. The claimant also sought an injunction before the High Court requiring deliveries of 570 packs of Kaletra® per month until trial.

In its judgment, the High Court began by stating that, to establish a claim, the claimant must first prove that the defendant is in a dominant position and, second, that it was abusing that position. As this was an application for interim relief, the claimant had to show that there was a serious question to be tried on those two issues and that, in this respect, the claimant had a "real prospect of success", and that the grant (as opposed to a refusal) of an interim injunction carried the least risk of injustice between the parties.

On the issue of dominance, the High Court observed that the first step was to define the relevant market. Here, the primary question was that of demand substitution. Basing itself on past case law, the High Court stated that it was very possible for a single patented medicine to be dominant in a market and, that such a medicine could constitute a distinct market of it own, but this remained rare and was a question of fact. Here, the fact that there was no generic equivalent for Kaletra® did not mean that such a medicine constituted a distinct product market. The focus of the argument therefore revolved around the extent to which patients could be prescribed alternative medicines or switch to other products at the start or after they commenced their treatment.

The High Court considered that the evidence showed that it was inappropriate to switch a patient on a protease inhibitor such as Kaletra® to another kind of agent and that care had to be taken before switching any medicine. Yet, other evidence also indicated that switching within categories of protease inhibitors was a possible alternative. Further evidence suggested that switching should only take place when it was clinically appropriate. However, the claimant had failed, in the High Court's view, to provide evidence to indicate what share of total purchases of Kaletra® in the UK came into this category nor was there any evidence on the share of total purchases of Kaletra® in the UK accounted for by new or existing patients. Without at least some information, it therefore seemed impossible to argue that a small but significant increase in the price of Kaletra® would not cause a sufficient degree of switching to one of the other protease inhibitors, such that this increase would not be profitable for the defendant.

The High Court also noted that there was no question that those patients that depended on Kaletra® as a truly life saving therapy and for whom no suitable alternative existed, of being denied supplies of their medicine. The defendant had made it clear all along that it would continue to supply the claimant with its requirements for its UK homecare business. However, on the facts, there was no real prospect of the particular ritonavir based protease inhibitor that is Kaletra® constituting a relevant product market by itself. There was, therefore, no serious question to be tried on the issue of dominance and the application fell to be dismissed.

The High Court nonetheless decided to address the issue of abuse for completeness and reminded that the refusal to supply by a dominant undertaking may, but will not necessarily, constitute an abuse of that dominant position. Qualified or conditional refusal, as in the present case, may also be abusive. Accordingly, refusal by an undertaking to meet orders of an existing customer constitutes abuse where, without objective justification, that conduct is liable to eliminate a trading party as a competitor. Similarly, a dominant undertaking cannot discontinue supplies to a long-standing customer who abides by regular commercial practice if the orders placed by that customer are in no way out of the ordinary.

The High Court referred in this respect to the Lelos ruling (Joined Cases C-468/06 to C-478/06, Sot. Lelos v GlaxosmithKline [2008] ECR I-7139), holding that Article 102 TFEU has never obliged a supplier to adopt a particular manner of distribution of its own products. In Lelos, the dominant undertaking actively supplied wholesalers in Greece but restricted volumes of supplies in order to limit their parallel exports to other Member States. Here, the defendant's policy was not to supply wholesalers in the UK at all. According to the High Court, if an undertaking supplies a customer on the basis that the supply is for retail sale and has a policy of not supplying wholesalers, the fact that, unknown to the supplier, its customer is reselling some of those products on the wholesale market does not mean that the customer's orders for the purpose of wholesale constitute "ordinary orders" or mean that the undertaking cannot adhere to its policy and practice of not supplying wholesalers once it finds out what has been going on. It is not necessary to show that the customer has been deceitful. However, the High Court did consider that the claimant's conduct had been disingenuous and did not constitute "regular commercial practice" (i.e., orders out of the ordinary in terms of quantity). The fact that some or all of the claimant's wholesale requirements were for parallel export trade could not make the defendant's conduct abusive either. Therefore, on these grounds, the High Court concluded there was, on the facts, no real prospect that the claimant could succeed in showing that if the defendant was in a dominant position, its conduct was abusive.

For all the above reasons, the High Court dismissed the application for interim relief.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.